| Issue Date |
Title |
Author(s) |
| 2021 |
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers |
Yang, Xu;Hu, Ying;Yang, Keyan;Wang, Dongxu;Lin, Jianzhen;Long, Junyu;Xie, Fucun;Mao, Jinzhu;Bian, Jin;Guan, Mei;Pan, Jie;Huo, Li;Hu, Ke;Yang, Xiaobo;Mao, Yilei;Sang, Xinting;Zhang, Jiao;Wang, Xi;Zhang, Henghui;Zhao, Haitao |
| 2018 |
Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression |
Lin, Jianzhen;Long, Junyu;Wan, Xueshuai;Chen, Jingci;Bai, Yi;Wang, Anqiang;Yang, Xiaobo;Wu, Yan;Robson, Simon C.;Sang, Xinting;Zhao, Haitao |
| 2019 |
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma |
Long, Junyu;Wang, Anqiang;Bai, Yi;Lin, Jianzhen;Yang, Xu;Wang, Dongxu;Yang, Xiaobo;Jiang, Yan;Zhao, Haitao |
| 6-Aug-2021 |
Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer |
Lin, Jianzhen;Peng, Xinxin;Dong, Kun;Long, Junyu;Guo, Xuejiao;Li, Hongyue;Bai, Yi;Yang, Xu;Wang, Dongxu;Lu, Xin;Mao, Yilei;Sang, Xinting;Ji, Xuwo;Zhao, Haitao;Liang, Han |
| 2021 |
Mutational spectrum and precision oncology for biliary tract carcinoma |
Lin, Jianzhen;Cao, Yinghao;Yang, Xu;Li, Guangyu;Shi, Yang;Wang, Dongxu;Long, Junyu;Song, Yang;Mao, Jinzhu;Xie, Fucun;Bai, Yi;Zhang, Lei;Yang, Xiaobo;Wan, Xueshuai;Wang, Anqiang;Guan, Mei;Zhao, Lin;Hu, Ke;Pan, Jie;Huo, Li;Lu, Xin;Mao, Yilei;Sang, Xinting;Zhang, Henghui;Wang, Kai;Wang, Xiaoyue;Zhao, Haitao |
| Aug-2020 |
Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma |
Lin, Jianzhen;Yang, Xu;Long, Junyu;Zhao, Songhui;Mao, Jinzhu;Wang, Dongxu;Bai, Yi;Bian, Jin;Zhang, Lei;Yang, Xiaobo;Wang, Anqiang;Xie, Fucun;Shi, Weiwei;Yang, Huayu;Pan, Jie;Hu, Ke;Guan, Mei;Zhao, Lin;Huo, Li;Mao, Yilei;Sang, Xinting;Wang, Kai;Zhao, Haitao |
| 2019 |
Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice |
Lin, Jianzhen;Dong, Kun;Bai, Yi;Zhao, Songhui;Dong, Yonghong;Shi, Junping;Shi, Weiwei;Long, Junyu;Yang, Xu;Wang, Dongxu;Yang, Xiaobo;Zhao, Lin;Hu, Ke;Pan, Jie;Sang, Xinting;Wang, Kai;Zhao, Haitao |
| 2018 |
Prognostic role of neutrophil-to-lymphocyte ratio in unresectable hepatocellular cancer patients treated with trans-arterial chemoembolization |
Xu, Weiyu;Xiong, Jianping;Lin, Jianzhen;Long, Junyu;Bai, Yi;Zheng, Yongchang;Xue, Hongyu;Sang, Xinting;Zhao, Haitao |
| Feb-2023 |
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients |
Yang, Xu;Chen, Bowen;Wang, Yanyu;Wang, Yunchao;Long, Junyu;Zhang, Nan;Xue, Jingnan;Xun, Ziyu;Zhang, Linzhi;Cheng, Jiamin;Lei, Jin;Sun, Huishan;Li, Yiran;Lin, Jianzhen;Xie, Fucun;Wang, Dongxu;Pan, Jie;Hu, Ke;Guan, Mei;Huo, Li;Shi, Jie;Yu, Lingxiang;Zhou, Lin;Zhou, Jinxue;Lu, Zhenhui;Yang, Xiaobo;Mao, Yilei;Sang, Xinting;Lu, Yinying;Zhao, Haitao |
| 2018 |
Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma |
Wang, Anqiang;Wu, Liangcai;Lin, Jianzhen;Han, Longzhe;Bian, Jin;Wu, Yan;Robson, Simon C.;Xue, Lai;Ge, Yunxia;Sang, Xinting;Wang, Wenze;Zhao, Haitao |
